Can a dose increase control lung cancer that Isn't shrinking?
NCT ID NCT07298148
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a higher dose (160 mg) of the drug firmonertinib can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer whose tumors have stayed stable but not shrunk after 8 weeks on the standard 80 mg dose. About 28 adults aged 18-75 with no prior treatment will take the higher dose daily. The main goal is to see if more tumors shrink or disappear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New targeted pill could boost lung cancer surgery success
- New antibody drug targets Cancer-Related fluid in the lungs
- New drug cocktail shows promise for Hard-to-Treat lung cancer
- New hope for lung cancer patients with brain-spread disease
- New hope for drug-resistant lung cancer: combo therapy enters trial
- New scan may reveal who will benefit from immunotherapy